An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...

Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...